Business Context and Reporting Period
This Form 8-K is a current report filed by Bone Biologics Corp, an emerging growth company incorporated in Delaware. The report covers events occurring on May 24, 2017, and was signed by the Chief Executive Officer on May 25, 2017.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
Effective May 24, 2017, William Coffin resigned as a director of the Company. No other material changes to operations or financial status are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to the notification of the director's resignation.
Investor Verification Checklist
- Confirm the effective date of William Coffin's resignation (May 24, 2017).
- Verify if the resignation was voluntary or due to a disagreement with the company.
- Check for any subsequent filings regarding the appointment of a replacement director.
- Review the company's latest 10-K or 10-Q for the most recent financial data, as this 8-K contains none.